Research
Hormonal
Astragalus polysaccharides (APS) improve T2DM outcomes by increasing the abundance of beneficial bacteria (e.g., Bifidobacterium, Lactobacillus) and short-chain fatty acids (SCFAs), while reducing insulin resistance.
Astragalus Polysaccharides (APS) may help manage blood sugar by promoting the growth of good gut bacteria. These bacteria produce short-chain fatty acids that improve insulin sensitivity. This suggests that gut health is a key part of managing T2DM, and Astragalus may support this process.
ModerateSupportsMEDIUM confidence
The primary impact of Astragalus polysaccharides (APS) on diabetes is a decrease in insulin resistance, encouragement of islet cell proliferation, and suppression of islet b cell death
Why this rating
Based on animal studies (db/db mice) and in vitro models; no human clinical data provided.
Source
Astragalus improves intestinal barrier function and immunity by acting on intestinal microbiota to treat T2DM: a research review
Su Min et al. · Frontiers in Immunology · 2023
DOI 10.3389/fimmu.2023.1243834
narrative_reviewCited 221×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Astragalus improves intestinal barrier function and immunity by modulating intestinal microbiota, thereby treating Type 2 Diabetes Mellitus (T2DM).Moderate
- Astragaloside IV (AS-IV), a saponin in Astragalus, reduces blood glucose and insulin resistance by modulating intestinal microbiota to increase butyric acid and activating PI3K/AKT and AMPK/SIRT1 signaling pathways.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →